CALL - SPRINTER OPEN END - VERTEX PHARMACEUTICALS | Market Closed - Deutsche Boerse AG 11:32:02 28/06/2024 pm IST | ||
| 13.1 EUR | +1.39% |
|
| Current month | +20.07% | ||
| 1 month | +24.52% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 13.1 | +1.39% |
| 27/24/27 | 12.92 | +0.31% |
| 26/24/26 | 12.88 | +0.94% |
| 25/24/25 | 12.76 | -2.67% |
| 24/24/24 | 13.11 | +5.22% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 11:32 pm IST
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VU8GFB |
| ISIN | DE000VU8GFB5 |
| Date issued | 13/06/2023 |
| Strike | 337.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.12 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.04 € |
|---|---|
| Lowest since issue | 2.28 € |
| Spread | 0.04 € |
| Spread % | 0.32% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Certificates
- Certificat
